Lilly reports all three doses met their goals at 80 weeks, with about 11% quitting on 12 mg and 13% reporting dysesthesia. Shares rose about 1% premarket.
Recap by typeshit. Full story at Stocktwits.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
A review recommends Ireland's health service weigh paying for the weight-loss drug, while warning the bill would run into billions of euro.
A short explainer from Dr Nadolsky on starting or restarting GLP-1 medication in the period after giving birth.
Loading…